 BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial, has been published in the peer-reviewed journal Nature Medicine. 